These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 36259089)

  • 1. The comparison of two different strategies of intravitreal conbercept for polypoidal choroidal vasculopathy in Chinese patients results from a 48-week randomized phase 4 study: STAR study.
    Li X; Qu J; Su G; Yu S; Zhang Y; Sadda SV;
    Acta Ophthalmol; 2023 May; 101(3):e327-e337. PubMed ID: 36259089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One-year results of intravitreal conbercept in treatment-naïve subjects with polypoidal choroidal vasculopathy.
    Ye LH; Cai Y; Shi X; Wong IYH; Qu JF; Zhao MW; Ying X; Li XX
    Graefes Arch Clin Exp Ophthalmol; 2021 Jun; 259(6):1455-1462. PubMed ID: 33146832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the First-Dose Anti-VEGF Anatomical Response in Polypoidal Choroidal Vasculopathy Patients: Correlation with the Third-Dose Response and Risk Factor Analysis.
    Wang Y; Zhang W; Yang J; Zhao X; Meng L; Chen Y; Zhang X;
    Ophthalmic Res; 2024; 67(1):85-95. PubMed ID: 38109862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective clinical trial of Intravitreal aflibercept treatment for PolypoIdal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results.
    Kokame GT; Lai JC; Wee R; Yanagihara R; Shantha JG; Ayabe J; Hirai K
    BMC Ophthalmol; 2016 Jul; 16():127. PubMed ID: 27465105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-Vascular Endothelial Growth Factor Therapy Regimens for Polypoidal Choroidal Vasculopathy: A Systematic Review.
    Mihalache A; Hatamnejad A; Patil NS; Popovic MM; Muni RH; Kertes PJ; Wong DT
    Ophthalmologica; 2023; 246(3-4):245-254. PubMed ID: 37591212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the Efficacy of Three Loading Doses of Intravitreal Injection of Conbercept with Injection Combined with PDT for the Treatment of PCV.
    Li F; Ma A; Zhao B
    Biomed Res Int; 2020; 2020():2428348. PubMed ID: 32382537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Intravitreal Aflibercept Treat and Extend for Polypoidal Choroidal Vasculopathy in the ATLANTIC Study: A Randomized Clinical Trial.
    Silva R; Arias L; Nunes S; Farinha C; Coimbra R; Marques JP; Cachulo ML; Figueira J; Barreto P; Madeira MH; Pires I; Sousa JC; Distefano L; Rosa P; Carneiro Â; Vaz-Pereira S; Meireles A; Cabrera F; Bures A; Mendonça L; Fernandez-Vega-Sanz A; Barrão S; Koh A; Cheung CMG; Cunha-Vaz JG; Murta J;
    Ophthalmologica; 2022; 245(1):80-90. PubMed ID: 34348351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term efficacy of intravitreal conbercept in treatment-naive patients with polypoidal choroidal vasculopathy.
    Peng Y; Zhang X; Li M; Liu B; Mi L; Zuo C; Wen F
    Drug Des Devel Ther; 2018; 12():339-345. PubMed ID: 29497280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-Year Results of a Treat-and-Extend Regimen of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy.
    Tamachi T; Kohno T; Yamamoto M; Hirayama K; Kyo A; Ueda N; Hirabayashi M; Shiraki K; Honda S
    Ophthalmol Ther; 2020 Dec; 9(4):1069-1082. PubMed ID: 33058069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in the ALTAIR Study: 96-Week Outcomes in the Polypoidal Choroidal Vasculopathy Subgroup.
    Okada AA; Takahashi K; Ohji M; Moon SC; Machewitz T; Sasaki K;
    Adv Ther; 2022 Jun; 39(6):2984-2998. PubMed ID: 35503499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK.
    Ogura Y; Jaffe GJ; Cheung CMG; Kokame GT; Iida T; Takahashi K; Lee WK; Chang AA; Monés J; D'Souza D; Weissgerber G; Gedif K; Koh A
    Br J Ophthalmol; 2022 Jul; 106(7):994-999. PubMed ID: 34301613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EFFICACY OF INTRAVITREAL INJECTION OF CONBERCEPT IN POLYPOIDAL CHOROIDAL VASCULOPATHY: Subgroup Analysis of the Aurora Study.
    Qu J; Cheng Y; Li X; Yu L; Ke X;
    Retina; 2016 May; 36(5):926-37. PubMed ID: 26595362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy.
    Morimoto M; Matsumoto H; Mimura K; Akiyama H
    Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):1891-1897. PubMed ID: 28669041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-Term Efficacy in Polypoidal Choroidal Vasculopathy Patients Treated With Intravitreal Aflibercept or Conbercept.
    Xue Y; Qinhua C
    Front Med (Lausanne); 2022; 9():835255. PubMed ID: 35252267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One-Year Efficacy and Safety of Proton-Beam Irradiation Combined with Intravitreal Conbercept for Refractory or Recurrent Polypoidal Choroidal Vasculopathy: A Pilot Study.
    Guo J; Qiu X; Tang W; Xu G; Moyers MF; Ren W; Xing Y; Gao J; Sun J; Lu J; Kong L; Liu W
    Ophthalmol Ther; 2022 Feb; 11(1):187-199. PubMed ID: 34773572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the 1-year Outcomes of Conbercept Therapy between Two Different Angiographic Subtypes of Polypoidal Choroidal Vasculopathy.
    Cheng Y; Shi X; Qu JF; Zhao MW; Li XX
    Chin Med J (Engl); 2016 Nov; 129(21):2610-2616. PubMed ID: 27779169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of polypoidal lesion-selective photodynamic therapy with intravitreal antivascular endothelial growth factor for polypoidal choroidal vasculopathy.
    Komuku Y; Iwahashi C; Gomi F
    Jpn J Ophthalmol; 2020 May; 64(3):265-270. PubMed ID: 32206935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy.
    Singh SR; Sahoo NK; Goud NR; Chhablani J
    Indian J Ophthalmol; 2019 Jul; 67(7):1114-1118. PubMed ID: 31238423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One-year outcomes of intravitreal conbercept combined rescue therapy for polypoidal choroidal vasculopathy in a Chinese population: a real-life clinical data.
    Qi HJ; Jin EZ; Zhao MW
    Int J Ophthalmol; 2019; 12(1):51-57. PubMed ID: 30662840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One-year outcomes of a treat-and-extend regimen of intravitreal aflibercept for polypoidal choroidal vasculopathy.
    Hosokawa M; Morizane Y; Hirano M; Kimura S; Kumase F; Shiode Y; Doi S; Toshima S; Hosogi M; Fujiwara A; Mitsuhashi T; Shiraga F
    Jpn J Ophthalmol; 2017 Mar; 61(2):150-158. PubMed ID: 27928695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.